Gabapentin for the Treatment of Patients With Somatization Disorder
J Clin Psychiatry 2001;62(6):474 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Somatization disorder is characterized by a pattern of multiple, clinically significant somatic complaints that cannot be fully explained by any known medical condition. The pharmacologic treatment of somatization disorder has scarcely been investigated owing to methodological problems, and no open or controlled trial has been conducted in patients with somatization disorder. Since pain is the most frequent symptom in somatization disorder, we selected gabapentin because it has demonstrated efficacy in patients with organic pain.